FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington	, D.C.	20549			

	OMB APP	ROVAL
OWNEDSHID	OMB Number:	3235-0287

0.5

3 IAI EIVIEN I OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3
	Estimated average bu	ırde
	hours per respense:	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 3	ee Instruction 1	0.																	
1. Name and Address of Reporting Person*  Rubin Eyal					2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [ PLX ]								(Cr	Relationship neck all app Direct	licable)	ng Per	rson(s) to Is 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET SCIENCE PARK, POB 455					3. Date of Earliest Transaction (Month/Day/Year) 09/23/2024												below)	, ,	
(Street)  CARMIEL L3 2161401  (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Table	I - Nor	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or l	Bene	eficia	ally Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da				y/Year) Execution		cution I	ution Date,				es Acquired (A Of (D) (Instr. 3,			Benefic	ies ially Following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A (D	(A) or (D) Pr		Transa	Transaction(s) (Instr. 3 and 4)			(111341. 4)
Common Stock 09/23/2					2024		A		99,010	1	A	(1)	) 669,010			<b>I</b> (2)	By Trust		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/I		4. Transa Code ( 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instrand 5	ative rities ired osed	6. Date Expirati (Month/	on Da Day/Y		Amo Secu Unde Deriv	Amo or Nun of	ount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.
- 2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

/s/ Eyal Rubin

09/24/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.